PharmaTher Collaborates with Craft Health to Evaluate CraftMake(TM) GMP-Ready Pharmaceutical 3D Printing Platform for Personalized Peptides
Toronto, Ontario--(Newsfile Corp. - July 29, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on personalized medicines, announced today a collaboration with Craft Health Pte. Ltd. ("Craft Health") to evaluate Craft Health's CraftMake™ GMP-ready pharmaceutical 3D printing platform for PharmaTher's Personaliz3D Peptides™ partner ecosystem. The collaboration will focus on developing novel pe
Biotechnologies, Pharmaceutique
2026-07-29 8:00 AM EDT | PharmaTher Holdings Ltd.
BioHarvest Sciences to Present at the Canaccord Genuity 46th Annual Growth Conference
British Columbia and Rehovot, Israel--(Newsfile Corp. - July 29, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will present at the upcoming Canaccord Genuity 46th Annual Growth Conference, to be held on August 11-13, 2026, in Boston, Massachusetts. In ad
Biotechnologies, Pharmaceutique, Santé
2026-07-29 8:00 AM EDT | BioHarvest Sciences Inc.
Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results
Calgary, Alberta--(Newsfile Corp. - July 28, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), an autologous (patient's own stem cells) regenerative medicine company is pleased to announce the VesCell™ Phase I Longevity Clinical Trial protocol has been drafted. The longevity protocol represents an important milestone in Hemostemix's strategy to expand the clinical application of VesCell™ beyond the treatment of card
Biotechnologies, Pharmaceutique, Santé
2026-07-28 12:14 PM EDT | Hemostemix Inc.
BioHarvest Sciences to Report Second Quarter 2026 Financial Results on August 11, 2026
British Columbia and Rehovot, Israel--(Newsfile Corp. - July 28, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that it will report its second quarter 2026 financial results before the market opening on Tuesday, August 11, 2026. The Company will host a conference call and webcast at 8:00 AM Eastern Time to discuss the r
Biotechnologies, Pharmaceutique, Santé
2026-07-28 8:00 AM EDT | BioHarvest Sciences Inc.
NuGen Adds to Core Patent Portfolio for Future Needle-Free Platforms
Toronto, Ontario--(Newsfile Corp. - July 27, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle-free drug delivery, today announced the filing of two additional patent applications supporting its current patent portfolio. The new applications focus on high-efficiency spring charging technology and automatic dose-establishment technology. Together with previously announced patent applications relating to the Company's dual-spring
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-27 5:15 PM EDT | NuGen Medical Devices Inc.
PreveCeutical Closes Third Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - July 27, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases dated June 12, 2026, May 12, 2026 and April 22, 2026, it has closed a third tranche (the "Third Tranche") of its previously announced non-brokered private placement (the "Offering"), which Third Tranche consisted of the issuance of 8,0
Biotechnologies, Pharmaceutique, Santé
2026-07-27 5:12 PM EDT | PreveCeutical Medical Inc.
PharmaTher Launches Personaliz3D Peptides(TM) to Advance Personalized Peptide Care Following Positive FDA Advisory Committee Recommendations
Toronto, Ontario--(Newsfile Corp. - July 27, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PH
Biotechnologies, Pharmaceutique
2026-07-27 8:00 AM EDT | PharmaTher Holdings Ltd.
Hemostemix Grants Stock Options
Calgary, Alberta--(Newsfile Corp. - July 22, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock option plan, it has granted on July 22, 2026, subject to regulatory approval, a total of 6,280,000 options to purchase common shares of Hemostemix (the "Options") to directors, officers, employees and consultants. Of the 6,280,000 Options granted, 4,535,000 Options vest immediately upon grant,
Biotechnologies, Pharmaceutique, Santé
2026-07-22 4:50 PM EDT | Hemostemix Inc.
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-22 12:30 PM EDT | Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-22 7:00 AM EDT | Phio Pharmaceuticals Corp.
Custom Health Announces Binding Letter of Intent to Acquire Evergreen Pharmacy; Expected to Add Over US$78 Million in Annual Revenue
Custom Health has entered into a binding letter of intent (the "LOI") to acquire Evergreen Pharmacy LLC ("Evergreen"), a Wisconsin-based specialty pharmacy specializing in the management of complex therapies for chronic disease states. Evergreen generated Revenue of approximately US$78.8 million with Normalized EBITDA (1) of US$0.60 million, for the twelve-month period ended December 31, 2025. Evergreen is a profitable company on both EBITDA an
Technologies, Pharmaceutique, Santé
2026-07-22 6:30 AM EDT | Custom Health Holdings Inc.
PharmaTher Enters into Collaboration Agreement for KetaMist(R) to Advance Needle-Free Ketamine Treatment Toward FDA Approval
Collaboration combines more than 9,000 KetaMist® patient treatments with PharmaTher's prior FDA-approved ketamine experience Pursuing an efficient FDA development pathway toward approval for treatment-resistant depression and other potential indications, leveraging KetaMist's real-world treatment foundation KetaMist represents a differentiated, patient-controlled ketamine platform with the potential to build a multi-indication ketamine franchise Tor
Biotechnologies, Pharmaceutique
2026-07-21 8:00 AM EDT | PharmaTher Holdings Ltd.
Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors
King of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that R. Todd Plott, M.D. has been appointed to the Board of Directors of Phio Pharmaceuticals. Todd Plott, MD, is a board-certified dermatologist, accomplished researcher, inventor, an
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-21 7:00 AM EDT | Phio Pharmaceuticals Corp.
Bachem Plans to Build a Large-Scale Production Facility in Sisslerfeld
Bubendorf, Switzerland--(Newsfile Corp. - July 21, 2026) - Bachem (SIX: BANB) announced today the sig
Biotechnologies, Produits chimiques, Soins de santé et hôpitaux, Pharmaceutique
2026-07-21 12:40 AM EDT | Bachem Holding AG
Richards Group Inc. Announces July 2026 Dividend
Toronto, Ontario--(Newsfile Corp. - July 20, 2026) - Richards Group Inc. (TSX: RIC) (the "Company") announced today its cash dividend for the month ended July 31, 2026 of Cdn$0.11 per share. This dividend will be to shareholders of record at the close of business on July 31, 2026 and will be payable on August 14, 2026. Shareholders who are non-residents of Canada may be required to pay all withholding taxes payable in respect of any dividends of income by the Company, whether such dividends
Soins de santé et hôpitaux, Produits ménagers / de consommation / cosmétiques, Pharmaceutique
2026-07-20 3:54 PM EDT | Richards Group Inc.
CBIH Unveils Cannabinoid-Based Intranasal Platform for Alzheimer's Research
Houston, Texas--(Newsfile Corp. - July 20, 2026) - Alzheimer's disease is not only a scientific challenge; it is a human crisis affecting millions of patients, families, caregivers, and healthcare systems. Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) is responding through an intranasal nanoemulsion platform designed to explore new possibilities in neurodegenerative care through cannabinoid-based and natural-compound science. CBIH's invention centers on an intranasal me
Biotechnologies, Pharmaceutique, Cannabis, Santé
2026-07-20 7:00 AM EDT | Cannabis Bioscience International Holdings
Voyageur Pharmaceuticals Announces the Engagement of Red Cloud Securities as Market Maker
Calgary, Alberta--(Newsfile Corp. - July 17, 2026) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company"), a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, is pleased to announce that it has engaged Red Cloud Securities Inc. ("Red Cloud"), subject to all required regulatory approvals, including the approval of the TSX Venture Exchange (the "TSXV") to provide market stabilization a
Pharmaceutique, Mines et métaux
2026-07-17 5:30 PM EDT | Voyageur Pharmaceuticals Ltd.
HarmonyRx Highlights 22 Years of Pharmacy Benefits Expertise, Building on Foundation as Broadreach Medical Research (BMR)
New York, New York--(Newsfile Corp. - July 15, 2026) - Since its founding as Broadreach Medical Research (BMR) in 2004, HarmonyRx has remained committed to transparency, clinical expertise and helping employers optimize pharmacy benefits. With more than two decades of experience in pharmacy benefits, HarmonyRx has grown alongside a rapidly changing healthcare landscape. As pharmacy costs have increased and benefit models have become more complex, the organization has remained focused on
2026-07-15 8:15 AM EDT | HarmonyRx
PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics
Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on personalized medicines, today provided a corporate update outlining its strategic focus on personalized medicines, specifically peptides and psychedelics. PharmaTher believes peptides and psychedelics are gaining strong momentum and plans to capitalize on this opportunity using its MEDBOTX™ 3D-printi
Biotechnologies, Pharmaceutique
2026-07-15 8:00 AM EDT | PharmaTher Holdings Ltd.
Extendicare Announces July 2026 Dividend of C$0.0441 per Share
Markham, Ontario--(Newsfile Corp. - July 15, 2026) - Extendicare Inc. (TSX: EXE) ("Extendicare" or the "Company") announced that it has declared a cash dividend of C$0.0441 per common share of the Company for the month of July 2026, which is payable on August 17, 2026 to shareholders of record at the close of business on July 31, 2026. This dividend is designated as an "eligible dividend" within the meaning of the Income Tax Act (Canada). About Extendicare Extendicare
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-15 8:00 AM EDT | Extendicare Inc.